GRITSTONE BIO, INC.

(GRTS)
  Report
Delayed Nasdaq  -  05/20 04:00:01 pm EDT
1.940 USD   -0.51%
05/17Gritstone to Participate in H.C. Wainwright Global Investment Conference
AQ
05/11TRANSCRIPT : Gritstone bio, Inc. - Shareholder/Analyst Call
CI
05/09HC Wainwright Lowers Gritstone bio's Price Target to $12 From $15, Maintains Buy Rating
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

GRITSTONE BIO, INC. : Results of Operations and Financial Condition (form 8-K)

01/10/2022 | 08:33am EDT

Item 2.02 Results of Operations and Financial Condition.

Gritstone bio, Inc. (the "Company") estimates that its cash, cash equivalents, marketable securities and restricted cash as of December 31, 2021 was approximately $223.5 million. The Company's actual consolidated cash, cash equivalents, marketable securities and restricted cash balance as of December 31, 2021 may differ from these estimates due to the completion of the Company's year-end closing and auditing procedures.

Spokespersons of Gritstone will be presenting the information provided in this item 2.02 of this Form 8-K at various upcoming meetings beginning January 10, 2022.

The information provided in this Item 2.02 of this Form 8-K shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any of the Company's filings under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses

All news about GRITSTONE BIO, INC.
05/17Gritstone to Participate in H.C. Wainwright Global Investment Conference
AQ
05/11TRANSCRIPT : Gritstone bio, Inc. - Shareholder/Analyst Call
CI
05/09HC Wainwright Lowers Gritstone bio's Price Target to $12 From $15, Maintains Buy Rating
MT
05/06CORRECTION -- Gritstone Reports First Quarter 2022 Financial Results and Provides Busin..
GL
05/06CORRECTION -- Gritstone Reports First Quarter 2022 Financial Results and Provides Busin..
GL
05/05GRITSTONE BIO, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RE..
AQ
05/05Earnings Flash (GRTS) GRITSTONE BIO Posts Q1 Revenue $7.2M, vs. Street Est of $4.21M
MT
05/05Gritstone Reports First Quarter 2022 Financial Results and Provides Business Update
AQ
05/05Gritstone bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
05/02Gritstone to Release First Quarter 2022 Financial Results on May 5 and Announces Q&A Op..
GL
More news
Analyst Recommendations on GRITSTONE BIO, INC.
More recommendations
Financials (USD)
Sales 2022 16,8 M - -
Net income 2022 -125 M - -
Net cash 2022 2,29 M - -
P/E ratio 2022 -1,23x
Yield 2022 -
Capitalization 141 M 141 M -
EV / Sales 2022 8,26x
EV / Sales 2023 -7,95x
Nbr of Employees 201
Free-Float 97,0%
Chart GRITSTONE BIO, INC.
Duration : Period :
Gritstone bio, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GRITSTONE BIO, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Last Close Price 1,95 $
Average target price 12,00 $
Spread / Average Target 515%
EPS Revisions
Managers and Directors
Andrew R. Allen President, Chief Executive Officer & Director
Vassiliki Celia Economides Chief Financial Officer & Executive Vice President
Elaine V. Jones Chairman
Karin Jooss Head-Research & Development
Erin E. Jones Chief Operating Officer
Sector and Competitors
1st jan.Capi. (M$)
GRITSTONE BIO, INC.-84.91%142
CSL LIMITED-5.75%93 171
SAMSUNG BIOLOGICS CO.,LTD.-10.52%44 721
BIOGEN INC.-19.52%28 278
WUXI BIOLOGICS (CAYMAN) INC.-43.60%28 063
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.-25.71%21 889